Treatment of acute and chronic constipation with bisoxatin acetate and bisacodyl. Double-blind crossover study.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J A Rider.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Diflunisal 1,000 mg/day, aspirin 4.0 g/day, or placebo were given to 36 healthy volunteers for 14 days to determine fecal blood loss. There was a significant increase in fecal blood loss from baseline in the aspirin group compared to both the diflunisal and placebo groups. A slight but significant increase in fecal blood loss in the diflunisal group at Week 1 was reported; however, there was no significant increase at Week 2. Use of diflunisal was not associated with any consistent blood loss or serious adverse reactions.